VUMC Reporter

Translational Therapeutics for Head and Neck Oncology Archives

Twenty-four hours after the administration of the study drug, catheters are inserted into the tumor and lasers emitting a wavelength of light that activates the dye molecule on the ASP-1929 are illuminated.

Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer

Oct. 14, 2021—Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.

Translational Therapeutics for Head and Neck Oncology Archives

Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer

Recent Stories from VUMC News and Communications Publications